Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Trastornos del Movimiento

5195 ARTÍCULOS , VIENDO DEL 1396 AL 1410

The Combination of rTMS and Pharmacotherapy on In Vitro Models: A Mini-Review

Pourzitaki C, Dardalas I, Poutoglidou F, Kouvelas D, Kimiskidis VK.

CNS Neurol Disord Drug Targets. 2020;19(3):220-226. doi: 10.2174/1871527319666200518100716.

Interlink Between Insulin Resistance and Neurodegeneration with an Update on Current Therapeutic Approaches

Bhattamisra SK, Shin LY, Saad HIBM, Rao V, Candasamy M, Pandey M, Choudhury H.

CNS Neurol Disord Drug Targets. 2020;19(3):174-183. doi: 10.2174/1871527319666200518102130.

Immunization therapies for Parkinson's disease: state of the art and considerations for future clinical trials

Antonini A, Bravi D, Sandre M, Bubacco L.

Expert Opin Investig Drugs. 2020 Jul;29(7):685-695. doi: 10.1080/13543784.2020.1771693. Epub 2020 Jun 12.

Dyspnea in Parkinson's disease: an approach to diagnosis and management

Vijayan S, Singh B, Ghosh S, Stell R, Mastaglia FL.

Expert Rev Neurother. 2020 Jun;20(6):619-626. doi: 10.1080/14737175.2020.1763795. Epub 2020 May 18.

Establishing apomorphine treatment in Thailand: understanding the challenges and opportunities of Parkinson's disease management in developing countries

Bhidayasiri R, Phokaewvarangkul O, Sakdisornchai K, Boonpang K, Chaudhuri KR, Parsons J, Lolekha P, Chairangsaris P, Srivanitchapoom P, Benedierks S, Panyakaew P, Boonmongkol T, Thongchuam Y, Kantachadvanich N, Phumphid S, Evans AH, Viriyavejakul A, Pisarnpong A, van Laar T, Jagota P.

Expert Rev Neurother. 2020 Jun;20(6):523-537. doi: 10.1080/14737175.2020.1770598. Epub 2020 Jun 2.

Orexin and Parkinson's disease: A protective neuropeptide with therapeutic potential

Liu C, Xue Y, Liu MF, Wang Y, Chen L.

Neurochem Int. 2020 Sep;138:104754. doi: 10.1016/j.neuint.2020.104754. Epub 2020 May 15.

The emerging role of α-synuclein truncation in aggregation and disease

Sorrentino ZA, Giasson BI.

J Biol Chem. 2020 Jul 24;295(30):10224-10244. doi: 10.1074/jbc.REV120.011743. Epub 2020 May 18.

Cardiac and neuronal HCN channelopathies

Rivolta I, Binda A, Masi A, DiFrancesco JC.

Pflugers Arch. 2020 Jul;472(7):931-951. doi: 10.1007/s00424-020-02384-3. Epub 2020 May 18.

Gene therapy for Parkinson's disease: contemporary practice and emerging concepts

Merola A, Van Laar A, Lonser R, Bankiewicz K.

Expert Rev Neurother. 2020 Jun;20(6):577-590. doi: 10.1080/14737175.2020.1763794. Epub 2020 May 19.

Nanotheranostic Applications for Detection and Targeting Neurodegenerative Diseases

Kumar A, Chaudhary RK, Singh R, Singh SP, Wang SY, Hoe ZY, Pan CT, Shiue YL, Wei DQ, Kaushik AC, Dai X.

Front Neurosci. 2020 Apr 30;14:305. doi: 10.3389/fnins.2020.00305. eCollection 2020.

Dietary Factors and Neurodegenerative Disorders: An Umbrella Review of Meta-Analyses of Prospective Studies

Barbaresko J, Lellmann AW, Schmidt A, Lehmann A, Amini AM, Egert S, Schlesinger S, Nöthlings U.

Adv Nutr. 2020 Sep 1;11(5):1161-1173. doi: 10.1093/advances/nmaa053.

Assessing the effect of current steering on the total electrical energy delivered and ambulation in Parkinson's disease

Hui D, Murgai AA, Gilmore G, Mohideen SI, Parrent AG, Jog MS.

Sci Rep. 2020 May 19;10(1):8256. doi: 10.1038/s41598-020-64250-7.

Voxel-wise meta-analysis of structural changes in gray matter of Parkinson's disease patients with mild cognitive impairment

Qin B, Yang MX, Gao W, Zhang JD, Zhao LB, Qin HX, Chen H.

Braz J Med Biol Res. 2020;53(6):e9275. doi: 10.1590/1414-431x20209275. Epub 2020 May 18.

Mitophagy in Parkinson's disease: From pathogenesis to treatment target

Dernie F.

Neurochem Int. 2020 Sep;138:104756. doi: 10.1016/j.neuint.2020.104756. Epub 2020 May 16.

Serotonin in Health and Disease

De Deurwaerdère P, Di Giovanni G.

Int J Mol Sci. 2020 May 15;21(10):3500. doi: 10.3390/ijms21103500.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias